SLC27A2 and neoplasm: Conversely, the deletion of FATP2 abolished the suppressive function of MDSCs and even blocked tumor progression in mouse models (EL4 lymphoma, Lewis lung carcinoma, and CT26 colon carcinoma, as well as in a genetically engineered model of pancreatic cancer), when used in combination with immune checkpoint inhibitors (87).